NCT05047718View on ClinicalTrials.gov

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

August 29, 2022

Study Completion Date

February 28, 2023

Conditions
Covid19
Interventions
BIOLOGICAL

COVID-19 vaccine Pfizer (3 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 vaccine Pfizer (2 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (3 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (2 doses)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

BIOLOGICAL

COVID-19 mRNA Vaccine Moderna (1 dose)

A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Trial Locations (2)

42055

CHU de Saint-Etienne, Saint-Etienne

69004

HCL - Hôpital Croix Rousse, Lyon

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

collaborator

Bioster, a.s.

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT05047718 - Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 | Biotech Hunter | Biotech Hunter